It is that time of year again when the biotech lens sets its focus squarely on San Francisco with more than 12,000 business executives, investors and analysts heading to town for the J.P. Morgan Healthcare, Biotech Showcase and OneMedForum events. The common denominator for all these meetings is money.

Reverse splits have a bad reputation amongst investors, causing biotechs, for the most part, to avoid them at all cost.